好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Sildenafil Alters Hippocampal Fractional Amplitude of Low Frequency Fluctuations (fALFF) in Patients with Alzheimer’s Disease
Aging, Dementia, and Behavioral Neurology
P6 - Poster Session 6 (11:30 AM-1:00 PM)
9-007

Sustained administration of PDE5 inhibitors improves memory, induces neuroplasticity and may reverse AD related histopathology in several transgenic mouse models of AD. Previous work involving the cohort of patients used in the present analysis has shown that sildenafil increases cerebral blood flow, particularly in the bilateral medial temporal lobes, at the expense of cerebrovascular reactivity, as well as increasing brain oxygen utilization. Here, we examine the fractional amplitude of low frequency fluctuations (fALFF) in the resting state fMRI BOLD signal (0.01 - 0.10 Hz) also collected before and after a single dose of sildenafil. Previous studies have demonstrated increased fALFF in hippocampi as well as parahippocampal gyri in patients with AD, so in this study we looked for evidence of reversal of such changes following sildenafil administration.

To analyze implications of alterations in the fractional amplitude of low frequency fluctuations (fALFF) in patients with Alzheimer’s disease (AD) after dosing with sildenafil, a selective phosphodiesterase 5 (PDE5) inhibitor.

We analyzed fALFF from 5 male and 5 female Caucasian participants with AD (MoCA average 18.2) before and after sildenafil administration to assess differences. Participants served as their own comparators.  

A significant decrease (p < 0.03) in fALFF was observed in the right hippocampus an hour after administration of 50 mg of sildenafil. Trend towards decrease was also observed in left parahippocampal gyrus, p = 0.08. 

Decreased fALFF in the hippocampus after acute sildenafil administration may represent a normalization of fALFF values in patients with AD. These data support the need for further investigation into the clinical effects of longer term sildenafil administration in patients with AD, extending previous basic science work. 

Authors/Disclosures
Niyatee Samudra, MD
PRESENTER
Dr. Samudra has nothing to disclose.
No disclosure on file
No disclosure on file
Ramon R. Diaz-Arrastia, MD, PhD, FAAN (University of Pennsylvania) Dr. Diaz-Arrastia has stock in BrainBox, LLC. Dr. Diaz-Arrastia has stock in Nia Therpeutics. The institution of Dr. Diaz-Arrastia has received research support from National Institutes of Health. The institution of Dr. Diaz-Arrastia has received research support from Department of Defense.
John Hart, MD (The University of Texas At Dallas) The institution of Dr. Hart has received research support from Department of Defense.
Kyle B. Womack, MD (Washington University School of Medicine) The institution of Dr. Womack has received research support from NIH. The institution of Dr. Womack has received research support from Janssen.